← All Sponsors

SPONSOR

AbbVie

Total Trials

17

Recruiting

17

Phases

Phase 3, Phase 2, Phase 1, Phase 2, Phase 1

Conditions studied: Breast Reconstruction Irritable Bowel Syndrome Plaque Psoriasis Major Depressive Disorder Multiple Myeloma Hidradenitis Suppurativa Atopic Dermatitis Advanced High-Grade Epithelial Ovarian Primary Peritoneal Fallopian Tube Cancers

NCT06575192 Phase 3

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Breast Reconstruction

NCT03339128 Phase 2

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Irritable Bowel Syndrome

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

NCT07276997 Phase 2

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

NCT06953960 Phase 1, Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Multiple Myeloma

NCT06524635 Phase 2

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Hidradenitis Suppurativa

NCT06682988 Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Advanced High-Grade Epithelial Ovarian

NCT07155174 Phase 2

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

NCT07207369 Phase 3

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

NCT06389136 Phase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic Dermatitis

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Diffuse Large B-cell Lymphoma

NCT07059845 Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT06673238 Phase 1

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

Healthy Volunteer

NCT07160179 Phase 1, Phase 2

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

NCT07024784 Phase 2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Gynecologic Cancers

NCT06902558 Phase 2

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

NCT06972446 Phase 2

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Rheumatoid Arthritis